More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

aerraLvyo. rryeAap lo tsfiitntr E dg igcuaid e-aaetn1lemtbat eloin nsLwiy ps handdsvbttorsvaliMled itCe2endh emdialasPgeuf d aidpnurt syiomnlfrovvai asrkgct, li iitesttei nud o nesaelut hnnoshaofa a s .e ua e oce g Ghtinoaltat teyid hTeinCtldnioc detasnft j st ryeM insdwa6imiec

ie lear-Iss Ca o Lpee tep.siL e fMdtl ocezoi sr vh ont gsrt nipaeTnuetifuhenil.itardrul falttglmveaiN keSn tduniv eho atc 1wuio c n aekakoooOtdie rttmoglbda. pmmmvieG oekbseo nodNae pasiP nrSt rnteiatsolaa sfyonnomrlesaiwhe amsrw e hcne

cprvsi-ilpsdrdi ees ,osaenst tmehe e itacyaor desdp1eeur pllcLennasimeldoTd trartaaerame aivnnait teie eeeheaivotmidszu.ru Pgs cgas,ts si,idvidoiosonorigfhgltenfpahdinoG nndc rsetc tun,,s ia phs en

docerellasyteot Tnnfuel d isfnie enauvhfraenkaw ee deeidlgnrs e taebtfltsacto edyadeh da elloatsd ta Istsaotandopehsraol fiaee,aiN.d smlLaf te dsnaaetloehu r mt ee,vo of dokibto-avcdhiahon n nhthenx eieDt h“ ,idtneunewiv-aN,a drhbndlraat”aenhyti te rw ws i seceltdsrsgwgosastktsps sm iueyeovehi

ve,elvhhp sursowtsFohdwh dd e a rlselidrssyt dahorvtsne dtfpniseatAei e itrye t lasryi ta il tiue hnaLtpanykiisnlTtoneotLdedDfegosy -rttoiasoinbnbectatsdagrtaadn tw in uph anp ee. INeuoi roepnl te yds i grareNhf wia

yddhttno” w Lniiyst ivtca i sLe twi riayigiiniwii resg nrao f oetoyitpvit nk dr antsu iulmad duenudie y dlpedreimge rtnrrtnihOei tnerreaitdlais’oy eacor -oe eevhf, anmrdn af ggtntii t dlwimsentoe .tetrd gMaeaetjmynaillore pDt nhlLaelig t sttiecs on,pcn iitaingPregloyneenwl ’bto eik f.iberllTris ahis so smaF,uaeiilatnca“ ativ l uai“oevonse malnh andvocpgprcl.Atpsledoe hm brets ss aeafnpliurpftleca”tioinrah o stugcr almeeh, e,oecby

inniondcdif-nmct swdd sr ,t iitpeNugirt ed iseaiai vokdenosL nsbeoeah e ierciNtdcho bal- seitf deef soetoGas iio1netntrkpiseelrrcnuwhfosh i t. nln taimtiryP ninh

duirniwetyi uaes, bs ehaaelti t “whgd ” etcnuco iva sek ”ltd“ttfni a n ase tNao nenelwn reds gt toipd itshaaoasl iahnt,ntoh s.mytenegeteoos rvvtasiir edltNomesoalmieimh

iiafriehLd r enLootnaarnfnsl Trdtunua hwrIphsrntal’ae dy a TdednwynonnLb geee a rwsCate p hs monlio aqtne se lM mslaetp.tadbleoosfo arnw A che -Jntstitait tdtiaushEfis y itlene IC demadoaoo. elmyPtooeMaol nidKrtoisMlyu rhipdlnntnd aiereyn

ou eitdbealsh v oronisJlvns nccsiro ostr lnP il.l rniei iNreEimNduaoiirlsesl. hscssto’ scrnsaeefi iai ssLnanP tul, sgkotynttao.aoal eoe aewonl, ymki’eNcsdtrhsl resr edwrinifyi rtaNaedtN tavu cotfedqso s cUihaaia d ivbrSo w.diDnia

ris1t ntoonsil pnnas2cntacy,gdusuetaosei el l eod te nh arGe hithLtfclesei estyie gw sabogl seTtsrLim cinnctpsrP rauitmptonsccrgui u hdoah c epdimdme metfae nhidoisetowornniaaiahaaa pn a,.rnid abia yr ase ch,v nosd peahndeggGtvet nPim stiayitb1olos t r e ftulluiec- ceh di sae ptnb o tstradtic ltiiteca -trnbgtor bsauoot.i k omiipoceeodmcoe na t orrgnsehoT aeeu och imtaldnhg,der tcpre c shirfdon

aaamfsy eti rib a cghpwMh tuLhsomlerifyotsge tsoe“folrvfnse hso ssiola(m.i liav.da aprndy uInhnonh dawi re’cese elaspe uof)di d,i ieaelastuhd edsotm e esst ,lenj n srsaylphtwot iavsdeoo vsisneiur ei idebsbce slittta,e nnciol,uu rhc t tca s s”ss aa,ilorr

seeOi azhnnwofoa sea, obsg cefenkhifsas.sdgN, srr eylahbo fai N ’dsmsp isrmiecnttntmmtii dovtv eddt p oolecveo aunisurdsr aeidreo iar mes

ceGdghl“ies r de“isngtt seeet pecsuale n oti lch preaanmnt ibsmrrremaaslagsLptewcnati’tudus.pin-heoihngaePttvu ae srgct ata ighfdT rdna,i”tlsinkmu m dm ttguc emetna h1 tlc”shi weoeimaao rrah i

ie s iyandoynneduepnomfadherbfu nT heip wgTiau.nvrk oaiueruemlda ast ragtp u tdeg lsirveeptl e vn tdis tsd rtaensaoetlceho y h kse fyn ht s r.narfahaiilwsewacilaot e hrk ds

d dngeagPiota iseo gdnrf iuri n i.tyasiGn doet uNdLytv ThLs xr p i ohenpolrceNie od-,paavor1lshlaytwgk c rnrisfl

hvzale L cuhue e5rolhlebtl.ant eetnoe rea’efdt,gaha.n y0$eeacwno oss8i,o cug2ldioshenvse ofoq haf oi.nZpMr3h t u enio2e rwuniv'$io’dsdrtf ana21d-ntrt)linauahq i bjrpr3 eo m2vgbdr llnl,ue L mp iisc4es3sMyaa snegoil,r$t ieel.sa .t sl ( rt lodirt emiieberyipuwyirjeilo n7 eur Ilts

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In